In This Section

AACR Special Conference: Rethinking DCIS: An Opportunity for Prevention?

September 8-11, 2022
Sheraton Philadelphia Downtown
Philadelphia, Pennsylvania

Abstract Submission DeadlineThursday, June 23, 2022, 12 p.m. ET
Advance Registration DeadlineThursday, July 29, 2022

Conference Cochairs:

Lisa M. Coussens, OHSU Knight Cancer Institute, Portland, Oregon
Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts
Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York


Please note that this meeting will take place as an in-person event in Philadelphia and will not live-stream content for virtual participation. The meeting content will be captured and made available as an on-demand program after the meting. Please see the Registration page for details.

Ductal carcinoma in situ (DCIS) is a proliferation of abnormal, but noninvasive, cells within the ductolobular system of the breast. DCIS is often considered stage 0 breast cancer and accounts for one in five newly diagnosed breast cancers in the US. Without treatment approximately 14-50% of DCIS will advance to invasive cancer. This large variation in disease progression underscores the need for better understanding of DCIS. Identification of DCIS subpopulations with malignant potential may also be reflective of the various forms of more advanced breast cancers and offers a unique opportunity to understand the complex ecosystem of breast cancer. This conference will utilize an interdisciplinary approach to explore the latest advances in the detection, biological understanding, risk assessment, and treatment of DCIS.   

Original artwork courtesy of Michael B. Endicott


Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available